Goldberg MS, Siegel JJ, Ahmed K, Kurley SJ, Farberg AS. A prospective clinical utility study demonstrates that physicians use the 40-gene expression profile (40-GEP) to guide clinical management decisions for Medicare-eligible patients with cutaneous squamous cell carcinoma (cSCC). J of Skin [Internet]. 2022 Nov. 16 [cited 2024 Jul. 23];6(6):s95. Available from: https://jofskin.org/33014/index.php/skin/article/view/1854